



MEMORANDUM

TO: Valued STAR and CHIP Providers

FROM: El Paso Health

DATE: 5/15/2024

RE: Change in Preferred Drug List Status for Lincosamides/Oxazolidinones/Streptogramins
Drug Class Effective May 6, 2024

Change in Preferred Drug List Status for Lincosamides/Oxazolidinones/
Streptogramins Drug Class Effective May 6, 2024.

The manufacturer of brand name Zyvox suspension, Pfizer, confirmed these products are on long term backorder. In response, the HHSC removed the non-preferred status from generic linezolid suspension products on the preferred drug list (PDL). The preferred status of brand name Zyvox suspension products will not change. This will allow the current stock of these medications to be used.

HHSC removed the non-preferred status for the following drugs, effective May 7, 2024

NDC	Label Name
00054031950	LINEZOLID 100 MG/5 ML SUSP
31722086525	LINEZOLID 100 MG/5 ML SUSP

These changes will allow providers to prescribe the generic linezolid suspension products without requiring a PDL prior authorization and continue accessing necessary medication for clients.

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com.